- Home
- DLY vs RIGL Comparison
DLY vs RIGL Comparison
Compare DLY & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DLY | RIGL |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.2M | 564.7M |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DLY | RIGL |
|---|---|---|
| Price | $14.02 | $40.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | 158.8K | ★ 386.8K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 8.93% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $93.09 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $13.51 | $18.70 |
| 52 Week High | $15.63 | $52.24 |
Technical Indicators
Market Signals| Indicator | DLY | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 64.43 |
| Support Level | $13.86 | $40.05 |
| Resistance Level | $14.10 | $44.85 |
| Average True Range (ATR) | 0.12 | 1.82 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 60.97 | 58.00 |
Price Performance
Historical ComparisonAbout DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.